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Myosin 1A (Myo1a) is a mechanoenzyme previously thought to be located exclusively in the intestinal
epithelium. It is the principle calmodulin-binding protein of the brush border. Based on earlier studies
in chickens, we hypothesized that Myo1a facilitates calcium transport across the brush border
membrane of the intestinal epithelium, perhaps in association with the calcium channel Trpv6.
Working with C2Bbe1 cells, a human intestinal epithelial cell line, we observed that overexpression of
Myo1a increased, whereas the antisense construct blocked calcium transport. To further test this
hypothesis, we examined mice in which either or bothMyo1a and Trpv6 had been deleted. Although the
Trpv6-null mice had decreased intestinal calcium transport, theMyo1a-null mouse did not, disproving
our original hypothesis, at least in mice. Expecting that a reduction in intestinal calcium transport
would result in decreased bone, we examined the skeletons of these mice. To our surprise, we found no
decrease in bone in the Trpv6-null mouse, but a substantial decrease in theMyo1a-null mouse. Double
deletions were comparable to the Myo1a null. Moreover, Myo1a but not Trpv6 was expressed in os-
teoblasts. In vitro, the bone marrow stromal cells from theMyo1a-null mice showed normal numbers of
colony-forming units but marked decrements in the formation of alkaline phosphatase–positive colonies
and mineralized nodules. We conclude that Myo1a regulates osteoblast differentiation independent of
its role, if any, in intestinal calcium transport, whereas Trpv6 functions primarily to promote intestinal
calcium transport with little influence in osteoblast function.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Intestinal calcium transport occurs by both the paracellular and transcellular routes (review
in Hoenderop et al. [1]). The transcellular route is themost regulated. The transcellular route
is comprised of three major processes: 1) calcium entry into the cell across the brush border
membrane down a steep electrochemical gradient through highly calcium-selective channels,
Trpv6 in particular; 2) transport through the cytosol mediated by calbindins CaBP9k
(mammals) or CaBP28k (avian); and 3) removal by an active calcium pump, members of the
PMCA family, at the basolateral membrane. 1,25 dihydroxyvitamin D [1,25(OH)2D] is the
major regulatory hormone stimulating intestinal calcium transport. 1,25(OH)2D induces
the brush border membrane calcium channel Trpv6 (previously known as ECAC2 or CaT1),
induces calbindin either 28k or 9k depending on species, and induces PMCA1b, the major
PMCA isoform in the intestine. The induction of Trpv6 by 1,25(OH)2D is faster than that of
Abbreviations: 1,25 (OH)2D, 1,25 dihydroxyvitamin D; mCT, micro-CT; AP, alkaline phosphatase; BMSC, bone marrow stromal cell;
BS, bone surface; BV, bone volume; CaM, calmodulin; CFU, colony-forming unit; CPC, cetylpyridinium chloride; DKO, double-
knockout; FCS, fetal calf serum; GFP, green fluorescent protein; KO, knockout; Myo1a, myosin 1A; OCN, osteocalcin; QPCR,
quantitative polymerase chain reaction; TRAP, tartrate-resistant acid phosphatase; TV, tissue volume; WT, wild-type.
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the other components [2, 3], and its expression is markedly reduced in mice lacking the
vitamin D receptor [4], suggesting that calcium entry across the brush border is the rate-
limiting step in 1,25(OH)2D-regulated intestinal calcium transport. Thus, there is great
interest in how this channel is regulated. Although induction of this protein by 1,25(OH)2D is
clearly one level of regulation, this mechanism would not suffice to adjust to rapid changes in
the calcium content following meals. Patch clamp studies indicate that Trpv6 calcium
channel activity is inhibited by high intracellular calcium levels [5, 6] mediated at least in
part by calmodulin (CaM), which binds the channel in a calcium-dependent manner [7, 8]. In
vitaminD–deficient animals, calcium accumulates just inside the brush bordermembrane [9,
10], and, therefore, would be expected to inhibit Trpv6 activity. Administration of 1,25(OH)2D
to vitamin D–deficient animals results in a flow of calcium out of the microvilli initially into
vesicles and mitochondria in the terminal web [11, 12]. This initial flow of calcium following
1,25(OH)2D administration occurs prior to and is independent of calbindin induction [13, 14],
but coincides with increased CaM translocation into the brush border [15].
Most of the CaM in the brush border is bound to myosin 1A (Myo1a), a single-headed
myosin previously thought to be expressed only in the intestinal epithelium that links the
actin core of the microvillus to the plasma membrane [16]. In chicken intestine, 1,25(OH)2D
increases the amount of CaM binding to Myo1a without stimulating the production of either
protein [17]. Myo1a is a mechanoenzyme with actin/Mg-activated ATPase activity that re-
quires CaM and micromolar levels of calcium to function [18]. However, its role in the brush
border remains poorly understood. We postulated that Myo1a plays a role in intestinal
calcium transport by regulating the levels of CaM and calcium in the vicinity of Trpv6 and so
controlling calcium flux through this channel. In this report, we show that overexpression of
Myo1a in C2Bbe1 cells enhances while inhibition of Myo1a expression inhibits 1,25(OH)2D-
stimulated intestinal calcium transport. Furthermore, Trpv6 forms a complex with Myo1a
and CaM, suggesting a direct interaction among Myo1a, CaM, and Trpv6 to regulate calcium
flux across the brush border. However, when we examined mice lacking Myo1a, we were
unable to demonstrate a reduction in calcium transport, unlike what we observed in the
Trpv6-null mouse, or to show that Myo1a deficiency further reduced calcium transport in
Trpv6-null mice.
Decreased intestinal calcium transport is well known to result in osteopenia/osteoporosis
(in calcium-deficient diets) or osteomalacia (in vitamin D–deficient diets). Thus, we examined
the bones of the Myo1a- and Trpv6-null mice, anticipating that reductions in intestinal
calcium transport would be reflected in changes in bone structure. Given the results of the
intestinal transport studies, we expected the Trpv6-null mice to be osteopenia, but not the
Myo1a-null mice. However, when we compared the bones of Trpv6 andMyo1a-null mice, only
the Myo1a-null mice showed an osteopenic phenotype. We then found that Myo1a was
expressed in osteoblasts, unlike Trpv6, in which its lack led to decreased osteoblast dif-
ferentiation. These surprising results suggest that at least inmice,Myo1a plays a greater role
in regulating bone formation than it does in intestinal calcium transport, revealing a pre-
viously undiscovered role for Myo1a that had previously been thought to function only in
the intestine.
1. Materials and Methods
A. Animals
Myo1a-null mice were a gift from Dr. Mark Mooseker. Trpv6-null mice were a gift from Dr.
Matthias Hediger. These were back bred into a C57BL/6 background. The mice were then
bred together to produce the double deletions. Control mice were C57BL/6 wild-type (WT)
used for the back breeding. Both sexes were included in all studies. For calcium transport
studies, the mice at weaning were placed on one of three diets differing only in calcium
content (0.02%, 0.42%, and 2.0%; Teklad 248060, 248134, and 248161, respectively; Envigo,
Somerset, NJ) for 2 weeks prior to study. For all other studies, the mice were raised on
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standard mouse chow (Teklad 8656; Envigo) containing 1.2% calcium. The right tibias were
obtained for micro-CT (mCT). The right distal femurs were obtained for trabecular bone
histomorphometry and immunohistochemistry. Left tibias and femurs were obtained for
mRNA determinations. Bone marrow stromal cells (BMSCs) from left tibias and femurs were
collected from individual mice for cell culture. These studies were approved by the Animal
Use Committee of the San Francisco VA Medical Center, where the animals were raised
and studied.
B. mCT
The tibias were analyzed with a Scanco Medical AG mCT apparatus (Scanco Medical AG,
Basserdorf, Switzerland) as previously described [19], following the guidelines developed by
Bouxsein et al. [20]. Measurements were made in the proximal tibia for trabecular bone and
just proximal to the tibiofibular junction for the cortical bone in 3-month-old mice.
C. Immunohistochemistry and Histomorphometry
To detect Myo1a expression by immunohistochemistry, the proximal tibia was fixed by 4%
paraformaldehyde in PBS overnight at 4°C and decalcified by 10% EDTA. The decalcified
tibias were then embedded in paraffin and cut into 5-mmsections. After deparaffinization and
rehydration, the sections were quenched with 3% hydrogen peroxide in methanol for 15
minutes to block endogenous peroxidase activity. Nonspecific binding was blocked using 4%
BSA in Tris-buffered saline for 30 minutes. Anti-Myo1a (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) [21] was applied to each section and incubated overnight at 4°C. The primary
antibody was detected with the rabbit-specific HRP/DAB detection IHC kit (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) [22] following themanufacturer’s instructions. Negative
controls were performed without the primary antibody. To assess trabecular bone volume
(BV) and bone resorption, proximal tibial sections were stained by hematoxylin and eosin
and by tartrate-resistant acid phosphatase (TRAP) staining for osteoclast detection. Tra-
becular BV/tissue volume (TV) and osteoclast number/bone surface (BS) were determined by
BIOQUANT (BIOQUANT Image Analysis Corporation, Nashville, TN).
D. Western Blotting
C2Bbe1 cells were plated into six-well plates at 50,000 cells/cm2 and allowed to grow to
confluency. They were then infected with vector only or WT sense or antisense adenovirus
constructs of the Myo1a–green fluorescent protein (GFP) clone at 1 3 107 plaque-forming
units/cm2. At 4, 7, 10, 13, 16, and 19 days postinfection, the cells were extracted in 200 mL
RIPA extraction buffer (50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 0.1% SDS, 150 mMNaCl,
and 1 mM EDTA) containing Complete Protease Inhibitor Cocktail (Roche Applied Science,
Indianapolis, IN) and 1mM4-(2-aminoethyl) benzenesulfonyl fluoride, HCl (Calbiochem, San
Diego, CA). Samples were sonicated, centrifuged to spin out debris, and subjected to SDS-
PAGE. Following electroblotting, the membranes were incubated in 1:5000 times chick gut
Myo1a monoclonal antibody (MAB 1647; Chemicon International, Temecula, CA) [23], fol-
lowed by 1:2000 times horseradish peroxidase–linked secondary antibody, incubation with
SuperSignal West Dura Extended Duration Substrate (Pierce Protein Research Products,
Rockford, IL), and autoradiography (BioMax MR; Kodak, Rochester, NY).
D-1. Cell culture
C2Bbe1. The C2Bbe1 clone of the cell line Caco2 (#CRL-2102; American Type Culture
Collection, Manassas, VA) was used for studies of calcium transport in vitro. Depending
on the experiment, these were plated on various support structures and grown in DMEM
containing 4.5 g/L glucose, L-glutamine, and sodium pyruvate, penicillin/streptomycin
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(Mediatech, Inc, Herndon, VA), 10% fetal calf serum (FCS; Atlanta Biologicals, Flowery
Branch, GA), and 0.01 mg/mL transferrin (Gibco/Invitrogen, Carlsbad, CA). The cells were
incubated at 37°C and 5% CO2 until assayed. Specifics for each type of experiment are
provided in the appropriate sections detailed later.
BMSCs. The left tibial and femoral BMSCs were harvested using techniques previously
described [19]. Briefly, the tibias and femurs were collected, and the soft tissue and the
epiphyses of each bone were removed. The bone marrow was flushed from the diaphysis
with a syringe and a 26-gauge needle. The marrow from each individual mouse was collected
in primary culture medium (a modification of Eagle medium containing L-glutamine and
nucleosides; Mediatech) supplemented with 10% fetal bovine serum (Atlanta Biologicals),
100 U/mL penicillin/streptomycin (Mediatech), and 0.25 mg/mL Fungizone (Life Technolo-
gies, Rockville, MD). A single-cell suspension was obtained by repeated passage through an
18-gauge needle. A pool of BMSCswasmade from the tibia and femur of eachmouse. The cells
were plated at 2 3 106 cells/well in six-well plates. Nonadherent cells were removed by
aspiration, and then the primary medium was replenished on day 5. On day 7, the cells were
provided with secondary medium [primary medium with 3 mM b-glycerophosphate (Sigma-
Aldrich, St. Louis, MO) and 50 mg/mL ascorbic acid (Sigma-Aldrich)]. Subsequent medium
changes were performed every 2 days for up to 21 days.
E. Adenoviral Constructs of Myo1a
The coding region sequence of Myo1a, previously cloned into the pEGFP-N1 vector (Clontech,
Palo Alto, CA), was released from the vector, along with the coding region for GFP, using SacI
and DraI restriction digestion (New England Biolabs, Beverly, MA) and then subcloned into
pAxCAwt using the manufacturer’s protocols (Takara Bio, Madison, WI). A 1-mL aliquot of the
ligated sample was packaged using a Gigapack III XL kit (Stratagene, La Jolla, CA) and
transfected into nonchemically competent DH5a cells (Clontech). PCR was used to confirm the
orientation of insert in either the sense or antisense direction. A forward primer for the
pAxCAwt vector (P1: 50-ACGTGCTGGTTGTTGTGCT-30) was combined with a reverse primer
for the 50 end of the Myo1a-GFP insert (S5: 50-AATTGTTGTTGCGAATGGT-30) or a reverse
primer for the 30 end of theMyo1a-GFP insert (AS5: 50-AGCTGAAGGGCATCGACTT-30). If the
insert is in the sense direction, the P1/S5 primer set will yield a 522-base pair product. If in the
antisense orientation, the P1/AS5 primer set will yield a 460-base pair product. Similarly, a
reverse primer on the pAxCAwt vector (P2: 50-TCCTTCCGAGTGAGAGAC-30) was combined
with a forward primer from the 30 end of the Myo1a-GFP (S3: 50-GAGGACGGCAACTACAAG-
30) or a forward primer from the 50 end of Myo1a-GFP (AS3: 50-ATTTGCCAATGCGTAGAT-30).
If the insert is in the sense direction, the P2/S3 primer set yields a 725-base pair product. If
inserted in the antisense direction, the P2/AS3 primer set yields a 500-base pair product. A
midscale cosmid prep was prepared from selected positive clones using the QIAfilter Midi Kit
(Qiagen, Valencia, CA) and transfected into HEK293 cells using the manufacturer’s protocols
(Takara Bio). Those wells showing lysis between days 10 and 13 were collected as clones. Each
clonewas tested for replication deficiency by infecting bothHEK293 cells andHeLa cells. Those
clones that lysed the HEK293 cells but did not lyse the HeLa cells were considered replication
deficient. These clones were multiplied through four seedings according to the manufacturer’s
protocol and the virus collected and stored at 280°C ready for use.
F. Colocalization
C2Bbe1 cells were seeded into 12-mmdiameter Transwell Clear Permeable Supports, 0.4-mm
pore size (Costar; Corning, Corning, NY) at a density of 50,000 cells/well in growth media
[DMEM plus 4.5 g/L glucose, L-glutamine, and sodium pyruvate plus penicillin/streptomycin
(Mediatech, Carlsbad, CA) with 10% FCS (Atlanta Biologicals, Flowerly Branch, GA) and
0.01 mg/mL transferrin (Gibco/Invitrogen)]. The cells were incubated at 37°C and 5% CO2
until confluency. The cells were then infected with adenovirus constructs for Myo1a-GFP at
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1 3 107 plaque-forming units/cm2. After 7 days of incubation, the cells were rinsed in calcium/
magnesium-free PBS and fixed in 3.7% formaldehyde in PBS. Cells were then permeabilized
with 0.1% Triton X-100 followed by counterstaining for actin with Texas Red–phalloidin
(Molecular Probes, Eugene, OR). The Transwell membrane was then cut away from the insert
and mounted on a microscope slide. Samples were examined by confocal microscopy for the
presence of GFP-labeledMyo1a and Texas Red–labeled actin. Computer-generated x-z sections
were generated and overlay images produced in Photoshop (Adobe Systems, San Jose, CA).
G. TRPV6 Antibody Production
In preparation for the coimmunoprecipitation and western blotting experiments, we gen-
erated an antibody to human TRPV6. The antibody was raised in rabbits against the TRPV6
peptide sequence NH3-SEDLDKDSVEKLELGC-COOH (ImmunoVision Technologies,
Brisbane, CA) [24]. This epitope corresponds to amino acids 656 to 671 of the human TRPV6
sequence (GeneBank accession number AAG41951.1). The second production bleed was
affinity purified against the peptide prior to use in western blots and immunoprecipitation.
H. CoImmunoprecipitation
C2Bbe1 cells were seeded and allowed to grow for 10 days postconfluence. The standard
growth media with 10% FCS was replaced with the same media containing 5% FCS. Cells
were treated with 13 1028 M 1,25 (OH)2D3 in 0.1% ethanol or vehicle for 72 hours, replacing
media and retreating every 24 hours. At harvest, cells were rinsed two times with calcium/
magnesium-free PBS, scraped into PBS containing protease inhibitors, transferred to a
dounce homogenizer on ice, and homogenized with 15 strokes. Each sample was centrifuged
at 100,000g for 30minutes at 4°C. The pellet was extracted in 1%Nonidet P-40, 2 mMEDTA,
150 mM NaCl, and 50 mM Tris, pH 8.0 (Sigma-Aldrich), containing Complete Protease
Inhibitors (Roche) and 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride, HCl (Calbiochem)
using dounce homogenization. The sample was spun at 16,000g to remove insoluble material,
precleared with A/G PLUS Agarose beads (Santa Cruz Biotechnology, Inc.), and then in-
cubated overnight with either 1:500 times anti-chick gut Myo1a monoclonal antibody as
noted previously or 1:500 times anti-TRPV6 rabbit polyclonal antibody. A/G PLUS Agarose
beads (Santa Cruz Biotechnology, Inc.) were added to the samples and tumbled 1 hour at 4°C.
The beadswerewashed and then extracted in 15mL two times sample loading buffer (625mM
Tris, pH 6.8, 20% glycerol, 20% SDS, and 0.1% bromophenol blue) prior to SDS-PAGE. The
blots were then probed forMyo1a, TRPV6, or CaM (1:800 CaM-FL rabbit polyclonal Ab; Santa
Cruz Biotechnology, Inc.) [25] and the signal detected as described previously.
I. Calcium Transport
In vitro, C2Bbe1 cells were seeded onto 24-mm, 0.4-mm pore Transwell Clear tissue culture
inserts (Costar; Corning) at 250,000 cells/well in 1.5 mL growth media per inner well and
2.0 mL growth media per outer well. At confluence, the cells were infected with adenovirus
constructs for Myo1a-GFP sense or antisense or vector only at 1 3 107 infectious particles/
cm2. Cells were incubated at 37°C and 5% CO2. On day 11 postinfection, the medium was
removed and replaced with 5% FCS containing media in both the inner and outer well. Cells
were treated with 13 1028 M 1,25(OH)2D3 in 0.1% ethanol or vehicle for 72 hours, replacing
media and treatments in both inner and outer wells every 24 hours. Calcium transport was
measured using the method of Fleet and Wood [26].
I-1. In vivo
The ligated in situ duodenal loop technique was used as we previously described [15]. Three
centimeters of the proximal portion of the duodenum is exposed, flushed with saline, ligated
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to form a loop with blood supply intact, and then injected with 100 mL PBS containing 1 mCi
45Ca in 1 mM calcium. Fifteen minutes later, at the time of euthanasia, the blood was ob-
tained by cardiac puncture and assessed for 45Ca. The data are expressed as: (counts per
minute)/20 mL serum/(counts per minute/20 mL loop media) 3 10,000.
J. Quantitative PCR
Total RNA was extracted from the BMSCs, intestinal mucosa, and tibial shaft (marrow
flushed out). The RNA was reversed transcribed into cDNA as previously described and
quantitated using the SYBR reagent or commercially obtained or custom-designed primers
and probes fromApplied Biosystems using the Applied Biosystems 7900HT (Foster City, CA)
as previously described [19, 27].
Quantitative polymerase chain reaction (QPCR) primer sets were: 1)Myo1a: forward primer,
50-ACCAGAGTTCATTGCCAAATACCGGGACTA-30 and reverse primer, 50-ACGTAGGACA-
TCACTAGCTTACTCGCCTCA-30; 2) Trpv6: primers and probe ordered from Applied Bio-
systems (MM00499078-M1); 3) GAPDH: forward primer, 50-TGCACCACCAACTGCTTAG-30
and reverse primer, 50-GGATGCAGGGATGATGTTC-30; 4) L19: forward primer, 50-CCAA-
GAAGATTGACCGCCATA-30, reverse primer: 50-GTCAGCCAGGAGCTTCTTGC-30, and probe,
Fam-CATCCTCATGGAGCACATCCACAA-BHQ; 5) alkaline phosphatase (AP): forward, 50-
TCCTGACCAAAAACCTCAAAGG-30, reverse, 50-TGCTTCATGCAGAGCCTGC-30, and probe,
50-CTGGTGGAAGGAGGCAGGATTGACC-30; 6) osteocalcin (OCN): forward, 50-CTCACAGA-
TGCCAAGCCCA-30, reverse, 50-CCAAGGTAGCGCCGGAGTCT-30, and probe, 50-CCCTGA-
GTCTCTGACAAAGCCTTCATGTCCA-30; and 7) CaM: forward, 50-GTGGATGCTGATGGTA-
ATGGC-30 and reverse, 50-TTCTCTGATCATTTCATCTACTTCTTCAT-30.
K. Determination of AP-Positive Colony Number and Calcium Nodule Formation
BMSCs were grown in six-well plates for up to 21 days. At day 7 of culture, the number of
colony-forming units (CFUs) per plate was determined. At day 14 of culture, cells were
fixed by 10% neutral buffered formalin and assessed using Sigma 104 Phosphate Sub-
strate (Sigma-Aldrich) to determine alkaline phosphatase (AP)-positive CFUs following the
manufacturers’ instructions. At day 21 of culture, calcium nodules were fixed by 10%
neutral buffered formalin and stained with 2% Alizarin Red (Sigma-Aldrich) for 10minutes.
The stain was aspirated and the dishes rinsed five times with distilled water to remove
loosely bound stain. The number of mineralized nodules was determined, and the spe-
cifically bound stain was eluted with a solution of 10% cetylpyridinium chloride (CPC) and
quantitated in a spectrophotometer at 540 nm.
L. Statistical Analysis
Data are presented as mean 6 SD. For the calcium transport studies, two-way ANOVA was
used. For the mCT studies, one-way ANOVA was used. Comparisons between genotypes for
mRNA and cell culture results were analyzed by Student t test. Statistical significance was
stated for P values ,0.05.
2. Results
A. Effect of Myo1a on Calcium Transport in vitro
To determine whether alterations in Myo1a levels would impact 1,25(OH)2D-regulated
intestinal calcium transport, we prepared an expression vector for Myo1a in the sense and
antisense direction. We plated C2Bbe1 cells on transwells and infected them with these
constructs when confluent. Control cells were infected with the empty adenovirus vector.
Figure 1 demonstrates that the sense construct localized appropriately to the brush border
membrane and that the sense construct increased and antisense construct decreased
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Myo1a expression in these cells. The endogenous Myo1a is seen as a 110-kD band, and the
GFP-Myo1a construct runs at 145 kD. The faint 125-kD band is not specific. The endog-
enous Myo1a increased with time after confluence in the control (WT) cells, but this was
blocked by both the antisense construct and sense construct. Although the inhibition of
endogenous Myo1a by the antisense construct is the expected result, its inhibition by the
sense construct even after it no longer expressed Myo1a is unclear. This could represent
prolonged inhibition of endogenousMyo1a expression by the initially elevatedMyo1a levels
or a nonspecific action of the viral construct itself. Overexpression of the sense construct
was maximal by 4 to 7 days after infection and decreased with time. Calcium transport
across these cells was measured on day 14 postinfection, following a 3-day period during
which 1028 M 1,25(OH)2D or its vehicle (ethanol) was administered daily. The time fol-
lowing infection to measure calcium transport was chosen to ensure both adequate en-
dogenous Myo1a expression in the vector only cells and only a modest overexpression of
Myo1a in the overexpressing cells. The experiments shown in Fig. 2 are representative of
three separate experiments for each condition, each performed with different preparations
of C2Bbe1 cells. 1,25(OH)2D stimulated calcium transport in the vector-infected cells by
fourfold to eightfold. Overexpression of Myo1a increased basal and 1,25(OH)2D-stimulated
calcium transport by ;50%. These increases were significant (P , 0.01). The antisense
construct had no effect on basal calcium transport, but inhibited 1,25(OH)2D-stimulated
calcium transport by ;80% (P , 0.02). In the vector only–treated cells, 1,25(OH)2D
Figure 1. (A) Myo1a colocalizes with actin in the brush border of intestinal epithelial
cells. C2Bbe1 cells were grown on Transwell inserts. At confluency, they were infected
with adenoviral constructs expressing full-length Myo1a fused with GFP. After 7 d, the
cells were stained with Texas Red–phalloidin to label actin and examined by confocal
microscopy. Myo1 colocalized with actin in the brush border. (B) Myo1a sense constructs
increase while antisense constructs of Myo1a decrease Myo1a expression in a time-
dependent fashion. C2Bbe1 cells were grown to confluency and then infected with vector
only (WT), a full-length antisense construct (AS), or the full-length Myo1a-GFP fusion
construct (S). At the indicated times, the levels of Myo1a were determined by western
analysis. The Myo1a-GFP fusion protein is expressed as a 145-kD protein, whereas the
endogenous Myo1a is expressed as a 110-kD protein. The antisense Myo1a construct
blocks endogenous Myo1a production, whereas the sense Myo1a-GFP construct
overexpresses the full-length Myo1a-GFP fusion protein. This experiment was repeated
twice with consistent results.
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stimulated Trpv6 expression sevenfold, but did not increase the expression of eitherMyo1a or
CaM (Fig. 3).
B. Myo1a Forms a Complex With CaM and TRPV6
To determine whetherMyo1a formed a complex with TRPV6 to enhance its ability to transport
calcium, C2Bbe1 cells were treated for 72 hours with 1028 M 1,25(OH)2D or vehicle (ethanol)
beginning on day 10 postconfluence. The cells were then lysed, the membrane extract im-
munoprecipitatedwith an antibody toMyo1a orTRPV6, and the immunoprecipitates evaluated
by western analysis for TRPV6, CaM, and Myo1a (Fig. 4). The TRPV6 antibody recognizes
a protein of ;85 kDa, although higher molecular weight forms are sometimes seen, which
are thought to represent different glycosylated forms of TRPV6 [6, 8]. The CaM antibody rec-
ognizes a 22-kDa band, indicating a low content of calcium in the CaM preparation, although
the breadth of the band indicates some residual calcium that affects it migration in the gel
[18]. The Myo1a antibody recognizes predominantly the 110-kDa band described previously.
Nonspecific IgG brought down none of these proteins (data not shown). 1,25(OH)2D increased
the total amount of TRPV6 and CaM in the lysate, but not that of Myo1a. The major point,
however, is that immunoprecipitation with an antibody to Myo1a coimmunoprecipitated
CaM and TRPV6, as did the antibody to TRPV6 coimmunoprecipitate Myo1a and CaM.
Figure 2. Overexpression of Myo1a enhances while inhibition of Myo1a expression blocks
1,25(OH)2D3-stimulated calcium transport. C2Bbe1 cells were grown to confluency on
Transwell inserts and then infected with vector only or the sense and antisense constructs of
Myo1a. After 11 d, the media was replaced and the cells treated with 10 nM 1,25(OH)2D3
daily for 3 d, at which point calcium transport (CaTx) was measured as described in
experimental procedures. 1,25(OH)2D3-stimulated calcium transport was increased by
overexpression of Myo1a (which also increased basal calcium transport) but was blocked by
inhibition of Myo1a expression using the antisense construct. The error bars enclose mean 6
SD of triplicate determinations. The white bars represent the vehicle-treated cells, and the
black bars are the cells receiving 1,25(OH)2D3. The experiment was repeated twice with
consistent results. *P , 0.01 compared vehicle-treated cells.
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B-1. Myo1a deletion unlike Trpv6 deletion failed to impact intestinal calcium
transport in vivo
To determine whether Myo1a was required for intestinal calcium transport in vivo, perhaps
in synergism with Trpv6, we examined intestinal calcium transport in single Myo1a- and
Trpv6-null mice and double-null mice at three different calcium concentrations (0.02%,
0.42%, and 2.0%). The mRNA levels in the intestine of the Myo1a-null and Trpv6-null mice
are shown in Fig. 5, demonstrating that the respective deletion of these genes is essentially
complete (undetectable). The mice were put on one of three calcium diets at weaning for
2 weeks prior to study. The results are shown in Fig. 6. The control mice did not show a
considerable decrease in calcium transport with the increase in dietary calcium, likely
reflecting the limited period (2 weeks) in which they were on the different calcium diets.
There was no notable reduction of calcium transport at the 0.02% and 0.42% calcium diet
level in theMyo1a-null mice compared with controls, although calcium transport was slightly
but significantly reduced on the 2% calcium diet. These results are in contrast to the marked
reduction in calcium transport in the Trpv6-null mice when fed the 0.42% and especially
the 2% calcium diet. Furthermore, lack of Myo1a did not alter the results in the Trpv6-
null mice. These results stand in contrast to the human intestinal cell line C2Bbe1, in
which overexpression and underexpression of Myo1a increased and decreased 1,25(OH)2D-
stimulated calcium transport, respectively, and an interaction between Myo1a and Trpv6
could be demonstrated.
C. Myo1a Deletion But Not Trpv6 Deletion Leads to Osteopenia
To determine whether these differences in intestinal calcium transport in the Myo1a- and
Trpv6-null mice had implications for the skeleton, we examined the tibiae and femora of these
mice at 3 months of age. At this time point, the Trpv6-null mice were comparable to controls
in terms of body weight, but theMyo1a-null and double-null mice were 15% and 22% smaller,
respectively, than the controls. The mCT results are shown in Fig. 7. The bones of theMyo1a-
null mice were smaller than their WT controls, as assessed by a 20% to 24% reduction in both
trabecular and cortical total volume, consistent with their reduced body weights. The bones
Figure 3. 1,25(OH)2D3 stimulates TRPV6 expression but not Myo1a or CaM expression.
C2Bbe1 cells were grown to 12 d postconfluency and then treated with 10 nM 1,25(OH)2D3
for 24 h. The RNA was extracted and analyzed for mRNA levels of Myo1a (BBM1), CaM,
Trpv6, and GAPDH using real-time QPCR. 1,25(OH)2D3 increased Trpv6 mRNA levels
nearly sevenfold, with no effect on CaM mRNA levels and a 25% reduction in Myo1a (BBM1)
mRNA levels. The error bars enclose mean 6 SD of triplicate determinations. Lack of an
error bar indicates an SD too small to be charted. The experiment was repeated twice with
consistent results. *P , 0.01 compared with vehicle treatment; **P , 0.001 compared with
vehicle treatment.
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Figure 4. Myo1a forms a complex with TRPV6 and CaM. C2Bbe1 cells were grown to 10 d
postconfluence then treated daily for 3 d with 10 nM 1,25(OH)2D3. At this point the cells
were lysed, centrifuged, and the 100,000g pellet extracted with 1% Nonidet P-40–containing
buffers as described in Materials and Methods. This extract was immunoprecipitated (IP)
with an antibody to (A) Myo1a or (B) TRPV6 and the IP analyzed for TRPV6, CaM, and
Myo1a. Both TRPV6 and CaM were coimmunoprecipitated with Myo1a in either case.
1,25(OH)2D3 increased the levels of TRPV6 and CaM and decreased the levels of Myo1a in
the membrane lysate but did not have a major impact on the ratio of these proteins in the
IP. This experiment was repeated three times with comparable results.
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from the Trpv6-null mice were not reduced in size relative to the WT controls and were even
slightly but significantly larger in the cortical bone. In theMyo1a-null mice trabecular BV/TV
was reduced 53%. Trabecular number was reduced by 16%, trabecular thickness by 23%, and
connectivity density by 64%. Cortical TV and BV were each reduced by equivalent amounts
(24% and 22%, respectively) such that BV/TV was not significantly altered. Cortical thick-
ness, likewise, was not significantly reduced [mean 6 SD, WT: 0.26 6 0.02 mm; Myo1aKO:
Figure 5. mRNA levels of Trpv6 and Myo1 are undetectable in the intestine of the
respective KO mice but robust in WT controls. The mRNA levels of Trpv6 and Myo1a from
the duodenal mucosa of 6 wk control (WT) and KO mice were measured by real-time QPCR.
In the respective KO mice, the mRNA levels of Trpv6 or Myo1a were undetectable with
robust expression in the controls. Results are expressed as mean 6 SD of triplicate
determinations from two different mice of each genotype. WT, black bars; Myo1a KO, white
bars; and Trpv6 KO, gray bars.
Figure 6. Intestinal calcium transport was reduced in Trpv6 KO and DKO mice but not
Myo1a KO mice. At weaning, the mice were placed on one of three diets (0.02%, 0.42%, and
2.0%) for 2 wk prior to evaluating calcium transport across the duodenum using the ligated
loop method. N 5 3 for each group on each diet. Only the Trpv6 KO and DKO mice showed a
reduction in calcium transport relative to controls, best seen at the higher dietary calcium.
Error bars enclose mean 6 SD. Data are expressed as a ratio of the counts in serum to the
counts in the ligated loop 3 10,000. The data were analyzed by two-way ANOVA. aIn the
same diet, significant difference from WT; bin the same diet, significant from TRPV6KO; cin
the same diet, significant when compared with DKO; din the same genotype, significant
when compared with 0.02% diet.
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0.24 6 0.02 mm; TRPV6 knockout (KO): 0.25 6 0.02 mm; and double KO (DKO): 0.24 6
0.02 mm], but the medullary volume of the Myo1a KO was reduced 31%. These data suggest
that the Myo1a KO favors endosteal to periosteal bone growth in comparison with controls
and the Trpv6 KO. The tibiae of the Trpv6 null mice, in contrast, did not show these re-
ductions, but rather were found to have higher BVs than controls with trabecular BV/TV
increased 80%, trabecular thickness increased 26%, and connectivity density by 112%.
Cortical BV and TV were increased 8% and 19%, such that the BV/TV was actually less than
control. Cortical thickness was not significantly altered but medullary volume was increased
42%, indicating that unlike the Myo1a KO, periosteal expansion was favored. The skeletal
measurements in the DKOmice were not significantly different from those in theMyo1a-null
mice, indicating that the lack ofMyo1a eliminated any impact on the skeleton induced by lack
of Trpv6. These results were very surprising, as up to now, Myo1a was thought to be re-
stricted to the intestinal epithelium, and our results with intestinal calcium transport led us
to anticipate that the Trpv6-null, not theMyo1a-null, mice would have the reduction in bone.
Thus, we further examined bone to determine whether Myo1a was expressed there and, if so,
what role it played.
D. Localization and Function of Myo1a in Osteoblasts
To determine whetherMyo1a is expressed in bone, immunohistochemistry using an antibody
against Myo1a was performed in the tibial sections of WT and Myo1a-null mice. As shown in
Fig. 8A, Myo1a is expressed in the osteoblasts on the BS and osteocytes embedded in bone
matrix in the tibias of the WT mice (Fig. 8A, WT), but the expression was abolished in the
Myo1a-null mice (Fig. 8A, KO). Consistent with the mCT measurements, histomorphometry
showed that the trabecular BV in theMyo1a-null mice (Fig. 8B, KO) was remarkably reduced
when compared with the WT mice (Fig. 8B, WT). In contrast, by TRAP staining, osteoclast
morphology was not altered in the Myo1a-null mice (Fig. 8C, KO) when compared with the
WTmice (Fig. 8C, WT). Quantitation of these data are shown in Fig. 8D. As shown in Fig. 8D,
TV (229%), BV (273%), and BV/TV (263%) were significantly decreased in the Myo1a-null
mice when compared with the WTs, confirming the bone loss in these mice. Compared with
the WTs, BS (265%) and total osteoblast number (265%) were remarkably decreased in the
Myo1a-null mice, although the osteoblast number/BS was comparable. Osteoclast number/
BS was likewise comparable in the WTs and KOs when normalized to BS, although overall
number was reduced given the reduced BS.
To further confirm the expression of Myo1a in bone, we isolated RNA from the tibia and
femur (marrow flushed out) and determined the mRNA levels of Myo1a by QPCR. As shown
in Fig. 9A, mRNA of Myo1a was expressed in the bones of WT mice (Fig. 9A, solid bars), but
essentially none in the bones of theMyo1a-null mice. In addition, no Trpv6 mRNAwas found
by QPCR in the bones from either WT mice or Myo1a-null mice (Fig. 9A, open bars). To
investigate the role of Myo1a in osteoblast differentiation, bone mRNA levels of AP and OCN
were determined by QPCR. Compared with the WT mice, a trend (not significant) toward a
reduction in mRNA levels of AP (Fig. 9B) and a marked reduction (50%) of mRNA levels of
OCN (Fig. 9C) were observed in the Myo1a-null mice. Runx2, RANK ligand, and RANK
mRNA levels were not significantly different (data not shown). These results suggest that
Myo1a stimulates the latter stages of osteoblast differentiation. To examine directly the
effects of Myo1a on osteoblast differentiation, BMSCs (osteoblast progenitors) were cultured
in vitro up to 21 days (Fig. 10). At day 7, there were no differences in CFUs (CFUs inWT, 156
2; KO, 19 6 5). At day 14 of BMSC culture, 40% fewer AP-positive colonies were formed in
the cultures from Myo1a-null mice than in the cultures from the WT mice (Fig. 10A). In
addition, at day 21 of BMSC culture, mineralization was also impaired in the cultures of the
Myo1a-null mice (Fig. 10B). The number of mineralized nodules and mineral content (eluted
by 10% CPC) was reduced by 76% and 88%, respectively, in the null mice cultures compared
with the WT cultures, confirming the QPCR results that Myo1a in osteoblasts is required for
their differentiation.
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Figure 7. Myo1a KO and DKO mice showed a reduction in (A) trabecular and (B) cortical
bone, but Trpv6 mice did not. The tibiae were obtained at 3 mo of age and their structures
assessed by mCT. The Myo1a-null but not the Trpv6-null showed a reduction in bone compared
with controls. N 5 6–12 for each genotype. One-way ANOVA was used to analyze the results.
The data are expressed as mean 6 SD. aSignificantly different from WT; bsignificantly different
from TRPV6 KO; csignificantly different from DKO. Conn.D, connectivity density; MV,marrow
volume; Tb.Th, trabecular thickness; Th.N, trabecular number.
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Figure 8. Expression of Myo1 in osteoblasts and the impact of its deletion on bone
histomorphometry. (A–C) Representative figures of WT (top) and KO (bottom) mice. (A)
Immunohistochemistry using an antibody against Myo1a identified Myo1a (brown) in the
osteoblasts (arrows) along the BS and osteocytes (arrowheads) within cortical bone in the
WT (top) mice, but the expression was abolished in the Myo1aKO (KO) mice. (B)
Histomorphometry confirmed that the trabecular BV was decreased in the KOs (bottom)
when compared with the WTs (top). (C) TRAP staining showed that the number of
osteoclasts (pink) in the BS was comparable in the WTs (top) and KOs (bottom). (A)
Magnification 340 and (C) 310 (scale bars, 50 mm); (B) 35 (scale bar, 100 mm). (D)
Trabecular bone histomorphometry measurements of WT (black bars) and KO (white bars).
*P , 0.05 WT vs KO. Ob.N, osteoblast number; Oc.N, osteoclast number.
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3. Discussion
This study began as an evaluation of the role of Myo1a in regulating intestinal cal-
cium transport, a role we hypothesized would involve regulation of the intestinal calcium
channel Trpv6. Trpv6 is well established as a 1,25(OH)2D-regulated calcium channel in the
intestinal brush border [1–3, 28], although its deletion does not prevent all of the 1,25(OH)2D-
stimulated active transport [29]. Studies with HEK293 cells or frog oocytes overexpressing
Trpv6 demonstrate its regulation by calcium, and this regulation appears to be mediated,
at least in part, by CaM, which binds to Trpv6 in a calcium-dependent fashion and in-
hibits its activity. Trpv6 is expressed at highest levels in the apical regions of the intestinal
villus [30, 31]. This is the same region where we [32] showed the greatest level of calcium-
accumulating ability by brush border membrane vesicles and highest levels of CaM and
Myo1a in the brush border. Therefore, we wanted to determine whether there was a link
between the increased binding of CaM to Myo1a in the brush border following 1,25(OH)2D
administration and Trpv6 regulation. Important for this concept is that earlier studies of
vitamin D–deficient animals with electron microscopic procedures identified calcium lining
the inside of the brush border plasmamembrane, which left themicrovillus following vitamin
D or 1,25(OH)2D administration [9–11]. Thus, the block in moving calcium through the
intestinal epithelium is not simply that of getting calcium into the microvillus, but getting it
out. Removing the microvillar calcium would then enable the Trpv6 channel to allow more
calcium into the cell. Therefore, we considered the possibility that Myo1a, by moving CaM in
and out of the microvillus with its bound calcium, could modulate these initial steps in
calcium transport. The dynamic binding of Myo1a within the microvillus (80% turnover in 1
minute using FRAP measurements with Myo1a-GFP expressed in LLC-PK1-CL4 cells [26])
support this possibility.
We first developed full-length Myo1a sense and antisense constructs to determine
whether we could enhance calcium transport by overexpressing Myo1a in C2Bbe cells or
inhibit calcium transport by blocking Myo1a expression. The sense construct colocalized
with actin in the brush border of these cells, as expected. The morphology of the cells was
not affected by these manipulations (data not shown). As expected, 1,25(OH)2D increased
calcium transport by these cells in confirmation of the work from other laboratories [33],
Figure 9. Bone expresses Myo1a but not Trpv6. Deletion of Myo1a reduces the expression of
OCN. mRNA levels from the tibial shaft of control and Myo1a 3-mo-old mice were measured
by real-time QPCR. (A) mRNA levels of Myo1a (black bars) and Trpv6 (white bars) in the
WT and Myo1aKO mice. Myo1a was expressed in the WT mice, but was completely
eliminated in the Myo1aKO mice. No Trpv6 expression was found by QPCR in either WTs or
Myo1aKOs, indicating Trpv6 is not expressed in bone. mRNA levels of (C) OCN were
significantly decreased in the Myo1aKOs (white bars) when compared with the WTs (black
bars), while no changes were observed in the mRNA levels of (B) AP between WTs and KOs.
Results are expressed as percentage of L-19 (housekeeper gene) (mean 6 SD). n 5 5 for WT;
n 5 3 to 4 for KO. *P , 0.05 vs WT.
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and this increase was accompanied by increased expression of Trpv6, also in confirmation of
the work of others [1–4, 34]. Overexpression of Myo1a increased while inhibition of Myo1a
expression blocked 1,25(OH)2D-stimulated calcium transport. Basal levels of calcium
transport were increased by overexpression of Myo1a, but inhibition of Myo1a expression
did not alter basal levels. Moreover, Myo1a formed a complex with Trpv6 and CaM in these
cells, supporting our hypothesis.
To test the role of Myo1a in intestinal calcium transport in vivo and its relationship with
Trpv6, we examined calcium transport in mice null for either Myo1a or Trpv6 or both. As
expected and in confirmation of the work of some [28] but not all [29, 35] studies, theTrpv6-null
mice showed a marked decrease in intestinal calcium transport compared with controls. Our
results differed from those of others [28, 29, 35] in that the differences in calcium transport
between null and controlmiceweremore readily seen inmice ingesting 0.42%and 2.0% calcium
diets than the 0.02% calcium diet, perhaps because we used a different technique (ligated loop
vs everted loop or oral gavage) in which compensatory factors for the loss of Trpv6 were blunted
by the higher calcium diet in this in vivo preparation measuring calcium transport from a
defined section of the intestine than in other preparations that are in vitro or not limited to the
Figure 10. BMSCs from Myo1a-null mice show reduced differentiation in vitro. BMSCs
were obtained from the femur and tibia of Myo1a-null and control mice (WT). On day 5, they
were switched to differentiation media, following which AP- expressing colonies were
quantitated on day 14 and Alizarin Red–stained mineralization nodules on day 21. As
shown, the BMSCs from the Myo1a-null mice (KO) have a marked reduction in (A) AP-
stained colonies and (B) mineralization nodule formation. The photos in A and B are
representative pictures of the cultures. The bar graph in A showed number of AP-positive
colonies/well in the WT and KO. The bar graphs in B showed number of mineralization
nodules per well (left) and the spectrum analyzer readings from each well after eluting with
10% CPC (right). For all bar graphs, results are expressed as mean 6 SD. Three wells for
each mouse. n 5 5 for WT; n 5 4 for KO. *P , 0.05 KO (white bars) vs WT (black bars).
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duodenum. This requires further investigation. More to the point of our hypothesis, theMyo1a-
null mice failed to show a defect in intestinal calcium transport and failed to alter (synergize
with) the reduced intestinal calcium transport in the Trpv6-null mice. This was surprising and
inconsistent with the in vitro studies using a human intestinal cell line. Thus, at least in mice,
Myo1a appears to have little impact on intestinal calcium transport. Understanding these
apparent species differences remains a topic for future investigation.
Anticipating that alterations in intestinal calcium transport would result in changes in
skeletal structure, we first performed mCT assessments of the tibiae of 3-month-old mice null
forMyo1a, Trpv6, or both (similar results were seen at 6 months, data not shown). Based on
the results with intestinal calcium transport and as previously reported [28, 36], we an-
ticipated that the Trpv6-null mice would have a skeletal phenotype, but not theMyo1a-null
mice, and that the double-null mice would resemble that of the Trpv6-null mice. To our great
surprise, our expectations were 180° wrong. The Trpv6-null mice showed an increase in
cancellous and cortical bone with increased trabecular thickness and connectivity density in
the proximal tibia, although cortical thickness was not altered. This is not a result of loss of
the Trpv6 in bone, as this protein is not expressed in bone to any extent, as we demonstrated
in this study in confirmation of the findings of others [36], although other Trpv channels such
as Trpv4 have been found in osteoblasts and influence calcium signaling in those cells [37].
Previous studies [36] with 2-month-old mice, presumably of the mixed B6/129 background,
likewise failed to show a reduction in BV/TV in the null mice on a normal diet, although it was
not increased, unlike our results. At this point, we have no clear explanation for the increased
bone seen in our Trpv6-null mice, although the increased PTH and 1,25(OH)2D found in other
studies in these mice [28, 29] may be more anabolic than catabolic under the conditions of
our experiments. This requires further investigation.
The greatest surprisewas the profound decrease in bone in theMyo1a-null mice, a loss that
dominated the anabolic changes found in theTrpv6-null mice when the double-null mice were
examined. This could not be explained by changes in calcium absorption from the intestine,
the only tissue previously known to express Myo1a. Exploring this unexpected result, we
demonstrated expression of Myo1a in the osteoblasts and osteocytes and found that in its
absence markers of osteoblast differentiation (OCN) were decreased. In vitro, BMSCs formed
fewer osteoblast colonies capable of expressing AP or mineralizing. We cannot say at this
point what role Myo1a is playing in osteoblasts. However, it is reasonable to anticipate that
its ability to interact with actin as a CaM-dependent mechanoenzyme plays a role in its
function in osteoblasts as it does in intestinal epithelial cells [38]. Transient dynamic actin
cytoskeletal changes have been shown to stimulate osteoblast differentiation [39], a role that
might require Myo1a. Similarly, calcium/CaM is well known to alter osteoblast proliferation
and differentiation in part through the regulation of CaM kinase II and calcineurin [40, 41].
Myo1a could alter the distribution of calcium/CaM within the cell, thus serving to regulate
access of these molecules to the enzymes regulating the differentiation process. These are
exciting observations of a potential player in skeletal growth. However, future studies are
required to elucidate this unexpected role of Myo1a in osteoblast differentiation and function.
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